Table 2 Characteristics of control subjects at baseline and after etanercept/placebo treatment
From: Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial
Before etanercept (n = 10) | Before placebo (n = 10) | After etanercept (n = 10) | After placebo (n = 10) | |
|---|---|---|---|---|
Sex (female/male) | 9/1 | 6/4 | - | - |
Age (years) | 69.9 ± 1.2 | 77.0 ± 5.7 | - | - |
BMI (kg/m 2 ) | 25.5 ± 0.9 | 26.4 ± 1.4 | - | - |
Blood pressure (systolic/diastolic, mmHg) | 148 ± 5/85 ± 3 | 150 ± 4/85 ± 2 | - | - |
Smokers (n) | 2 | 3 | - | - |
Hypertension (n) | 5 | 4 | - | - |
Hypercholesterolemia (n) | 2 | 1 | - | - |
Physical activity level (1, high; 2, medium; 3, low) | *1.5 ± 0.2 | *1.9 ± 0.1 | *1.6 ± 0.2 | *1.8 ± 0.2 |
ESR (mm/hr) | *11.0 ± 3.1 | *9.1 ± 1.3 | *9.4 ± 2.8 | *13.5 ± 1.2 |
CRP (mg/dl) | *1.1 ± 0.1 | * < 1.0 | * < 1.0 | * < 1.0 |
Elevation of arms (3-0) | *0 | *0 | *0 | *0 |
Morning stiffness (min) | *6.0 ± 2.0 | *0 | *0 | *0 |
Physician's global assessment, VAS (0-10 cm) | *0.2 ± 0.2 | *0 | *0 | *0 |
Subjects' assessment of pain, VAS (0-10 cm) | *0.75 ± 0.5 | *1.0 ± 0.4 | *0.06 ± 0.1 | *0 |